Table 1.
Baseline characteristics and medication use on the day of starting cinacalcet treatment.
| Characteristicsa | Total (n = 135) | G carriers (n = 103) | G noncarriers (n = 32) | p valueb |
|---|---|---|---|---|
| Male, n (%) | 66 (48.9) | 48 (46.6) | 18 (56.3) | 0.340 |
| Body weight, kg | 56.0 (49.8, 66.5) | 54.9 (49.8, 64.4) | 61.3 ± 15.1 | 0.380 |
| Age, years | 59.5 ± 13.2 | 58.8 ± 13.3 | 61.7 ± 12.8 | 0.273 |
| Dialysis duration, years | 4.0 (2.4, 6.0) | 4.0 (2.4, 6.0) | 4.3 ± 2.9 | 0.752 |
| Dialysate calcium, mEq/L | 2.5 (2.5, 3.0) | 2.5 (2.5, 3.0) | 2.5 (2.5, 3.0) | 0.200 |
| Serum iPTH, pg/mL | 1262.0 (1018.0, 1633.0) | 1237.0 (990.1, 1622.0) | 1390.0 ± 336.6 | 0.152 |
| Serum calciumc, mg/dL | 9.7 (9.3, 10.3) | 9.8 ± 0.8 | 9.9 ± 0.8 | 0.483 |
| Serum phosphate, mg/dL | 4.7 ± 1.4 | 4.7 ± 1.5 | 4.7 ± 1.2 | 0.934 |
| Serum ALP, U/L | 144.0 (103.0, 240.0) | 139.0 (102.0, 226.0) | 185.0 (110.0, 255.0) | 0.159 |
| Serum creatinine, mg/dL | 9.2 (7.8, 11.2) | 9.2 (7.8, 11.0) | 9.2 (7.9, 11.5) | 0.610 |
| Serum 25-(OH)Dd, ng/mL | 25.5 (19.4, 33.4) | 25.5 (19.6, 33.8) | 25.3 ± 7.8 | 0.313 |
| Medications: | ||||
| Phosphate binders | ||||
| Calcium carbonate, n (%) | 36 (26.7) | 31 (30.1) | 5 (15.6) | 0.106 |
| Lanthanum carbonate, n (%) | 60 (44.4) | 42 (40.8) | 18 (56.3) | 0.124 |
| Sevelamer carbonate, n (%) | 32 (23.7) | 24 (23.3) | 8 (25.0) | 0.844 |
| Aluminium hydroxide, n (%) | 4 (3.0) | 4 (3.9) | 0 | 0.258 |
| Calcitriol & vitamin D analog | ||||
| Calcitriol, n (%) | 35 (25.9) | 26 (25.2) | 9 (28.1) | 0.745 |
| Calcitriol dose, μg/week | 1.5 (0.8, 3.0) | 1.5 (0.8, 3.0) | 2.3 (1.0, 4.0) | 0.392 |
| Alfacalcidol, n (%) | 37 (27.4) | 30 (29.1) | 7 (21.9) | 0.422 |
| Alfacalcidol dose, μg/week | 2.3 (1.5, 3.8) | 3.0 (1.5, 4.0) | 1.5 (1.5, 2.3) | 0.123 |
| Vitamin D | ||||
| Ergocalciferol, n (%) | 72 (53.3) | 54 (52.4) | 18 (56.3) | 0.705 |
| Ergocalciferol dose, *20,000 IU/month | 4.0 (4.0, 12.0) | 4.0 (4.0, 10.0) | 4.0 (4.0, 12.0) | 0.595 |
iPTH intact parathyroid hormone, ALP alkaline phosphatase, 25-(OH)D 25-hydroxy vitamin D.
aContinuous data are expressed with either means ± standard deviations if they are normally distributed or medians (interquartile ranges) if they are not normally distributed.
bThe p values were calculated with the use of the chi-square test, the Mann–Whitney U test, or the t-test for comparison between G carriers and noncarriers.
cSerum calcium is reported as albumin corrected values if serum albumin was less than 4.0 g/dL [corrected calcium in mg/dL = measured calcium in mg/dL + 0.8*(4—serum albumin in g/dL)].
dSerum 25-(OH)D was that of 126 patients only.